Preventative effect of deferoxamine on degenerative changes in the optic nerve in experimental retrobulbar haematoma

Clinical and Experimental Ophthalmology

Volumn 31, Issue 1, 2003, Pages 66-72

  Pelit, Aysel ^a   Haciyakupoglu, Gülhanim ^b   Zorludemir, Suzan ^b   Mete, Ufuk ^b   Daglioglu, Kenan ^b   Kaya, Mehmet ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Deferoxamine; Electron microscopic examination; Iron; Optic neuropathy; Retrobulbar haemorrhage

Indexed keywords

DEFEROXAMINE; IRON; THIOPENTAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ULTRASTRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG EFFICACY; ELECTRON MICROSCOPY; ENUCLEATION; LABORATORY TEST; NONHUMAN; OPTIC NERVE; RABBIT; RETROBULBAR HEMORRHAGE; RETROBULBAR OPTIC NEUROPATHY; STAINING;

ANIMALS; DEFEROXAMINE; DISEASE MODELS, ANIMAL; HEMATOMA; IRON CHELATING AGENTS; NERVE DEGENERATION; OPTIC NERVE; OPTIC NERVE DISEASES; RABBITS; RETROBULBAR HEMORRHAGE;

EID: 0037297556     PISSN: 14426404     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-9071.2003.00603.x     Document Type: Article

References (42)

1. Neave V, Weiss HM. Neurological evaluation of a patient with head trauma. In: Wilkins R, Rengachory SS, eds. Neurosurgery, New York: McGraw Hill, 1985; 1577-84.
2. Heinze JB, Hueston JT. Blindness after blepharoplasty. Mechanism and early reversal. Plast Reconstr Surg 1978; 61: 347-354.
3. Katz B, Herschler J, Brick DC. Orbital haemorrhage and prolonged blindness: A treatable posterior optic neuropathy. Br J Ophthalmol 1983; 67: 549-53.
4. McCartney LD, Char HD. Return of vision following orbital decompression after 36 hours of postoperative blindness. Am J Ophthalmol 1985; 100: 602-4.
5. Gordon S, Macrae M. Monocular blindness as a complication of treatment of a molar fracture. Plast Reconstr Surg 1950; 6: 228.
6. Cionni RJ, Osher RH. Retrobulbar hemorrhage. Ophthalmology 1991; 98: 1153-5.
7. Hay A, Flynn HW, Hoffman SI, Rivera AH. Needle penetration of the globe during retrobulbar and peribulbar injections. Ophthalmology 1991; 98: 1017-24.
8. Hornblass A, Mines JA. Transient visual loss following palpebral dacryoadenectomy and intraorbital hemorrhage. Ophthalmic Surg 1982; 13: 815-18.
9. Kremer I, Nissenkorn I, Feuerman P, Ben-Sira I. Congenital orbital vascular malformation complicated by massive retrobulbar hemorrhage. J Pediatr Ophthalmol Strabismus 1987; 24: 190-93.
10. Rootman J, Hay E, Graeb D, Miller R. Orbital-adnexal lymphangiomas. A spectrum of hemodynamically isolated vascular hematomas. Ophthalmology 1986; 93: 1558-70.
11. Rubinstein RA, Albert DM, Scheie HG. Ocular complications of hemophilia. Arch Ophthalmol 1966; 76: 230-32.
12. Mahaffey PJ, Wallace AF. Blindness following cosmetic blepharoplasty. Br J Plast Surg 1986; 39: 213-21.
13. Bonito V, Agostinis C, Ferranesi S, Defanti CA. Superficial siderosis of the CNS after brachial plexus injury. J Neurosurg 1994; 80: 931-4.
14. O'Riordan JI, Javed M, McShane D, Hutchinson M, Murphy R. Superficial siderosis of the central nervous system. Ir J Med Sci 1996; 165: 182-4.
15. Ozawa H, Nishida A, MIto T, Takashima S. Ferritin immunohistochemical study on pontine nuclei from infants with pontosubicular neuron necrosis. Brain Dev 1995; 17: 20-23.
16. Wise JB. Treatment of experimental siderosis bulbi vitreus hemorrhage and corneal blood staining with deferoxamine. Arch Ophthalmol 1966; 75: 698-707.
17. Valvo A. Desferrioxamine B in ophthalmology. Applications and therapeutic possibilities. Am J Ophthalmol 1967; 63: 98-103.
18. Declercq SS. Desferrioxamine in ocular siderosis: A long-term electrophysiological evaluation. Br J Ophthalmol 1980; 64: 626-9.
19. Young VL, Gumucio CA, Lund H. Long-term effect of retrobulbar hematomas on the vision of cynomolgus monkeys. Plast Reconst Surg 1992; 89: 70-75.
20. Osaka K. Prolonged vasospasm produced by the breakdown products of erythrocytes. J Neurosurg 1977; 47: 403-11.
21. Alm A, Bill A. Ocular and optic nerve blood flow at normal and increased intraocular pressure in monkeys (Macaca irus): A study with radioactively labelled microspheres including flow determination in brain and some other tissues. Exp Eye Res 1973; 15: 15-30.
22. Glaser JS. Anatomy of the visual sensory system. In: Duane TD, ed. Clinical Ophthalmology, Vol. 1. Philadelphia: Harper & Row, 1980; 1-13.
23. Janss AJ, Galetta JL, Freese A et al. Superficial siderosis of the central nervous system: Magnetic resonance imaging and pathological correlation. J Neurosurg 1993; 79: 756-60.
24. Ganong WF, ed. Review of Medical Physiology. New York: Lange, 1996.
25. Guyton AC, Hall JE, eds. Textbook of Medical Physiology. Philadelphia: WB Saunders, 1996.
26. Avunduk AM, Yardimci S, Avunduk MC, Kurnaz L. Cataractous changes in rat lens following cigarette smoke exposure is prevented by parenteral deferoxamine therapy. Arch Ophthalmol 1999; 117: 1368-72.
27. Echlin FA. Spasm of basilar and vertebral arteries caused by experimental subarachnoid hemorrhage. J Neurosurg 1965; 23: 1-11.
28. Marshall WH. Delayed arterial spasm following subarachnoid hemorrhage. Radiology 1973; 106: 325-7.
29. Kapp J, Mahaley MS, Odom GL. Cerebral arterial spasm. Experimental evaluation of mechanical and humoral factors in pathogenesis. J Neurosurg 1968; 29: 339-49.
30. Simeone FA, Vinall P. Mechanisms of contractile response of cerebral artery to externally applied fresh blood. J Neurosurg 1975; 43: 37-48.
31. Horky LL, Pluta RM, Booch RJ, Oldfield EH. Role of ferrous iron chelator 2,2′-dipyridly in preventing delayed vasospasm in a primate model of subarachnoid hemorrhage. J Neurosurg 1998; 88: 298-303.
32. Regan RF, Panter SS. Hemoglobin potentiates excitotoxic injury in cortical cell culture. J Neurotrauma 1996; 13: 223-31.
33. Bioos R, Macfarlane RG, eds. Human Blood Coagulation and Its Disorders. Oxford: Blackwell Scientific Publications, 1962.
34. Bickel H, Gacumann E, Keller-Schierlein W et al. On iron containing growth factors, sideramines, and their antagonists the iron-containing antibiotics, sideromycins. Experientia 1960; 16: 129-33.
35. Klaassen CD. Heavy metals and heavy metal antagonists. In: Goodman AG, Molinoff PB, Limbird LE, Hardman JG, eds. The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw Hill, 1996; 1649-71.
36. Sarioglu Y, Utkan T, Akgün M, Düzcan E, Utkan NZ. Effects of deferoxamine and sympathectomy on endothelin-1 induced contraction and acetylcholine-induced relaxation following sabarachnoid hemorrhage in carotid artery. General Pharmacol 1997; 28; 145-51.
37. Marciani MG, Cianciulli P, Stefanini F et al. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: An electrophysiological study of cerebral and visual function. Haematologica 1991; 76: 131-4.
38. Olivieri NF, Bungic R, Chaw E, Gallant T, Harrison RV, Keenan N. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314: 869-73.
39. Van Landeghem GF, D'Haese PC, Lamberts LV, Barata JD, De Broe ME. Aluminium speciation in cerebrospinal fluid of acutely aluminium-intoxicated dialysis patients before and after desferrioxamine treatment: A step in the understanding of the element's neurotoxicity. Nephrol Dial Transplant 1997; 12: 1692-8.
40. Triantafyllov N, Fisfis M, Sideris G et al. Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long term desferrioxamine (DFO) treatment. Acta Neurol Scand 1991; 83: 306-8.
41. Arden GB, Kennedy WB, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 1984; 68: 873-7.
42. Gelmi C, Borgna PC, Franchin S, Tacchini M, Trimarchi F. Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major. Ophthalmologica 1988; 196: 29-34.